Is Azenta, Inc. overvalued or undervalued?

As of 21 November 2025, the valuation grade for Azenta, Inc. has moved from risky to attractive, indicating a more favorable outlook. The company appears to be undervalued, particularly when considering its Price to Book Value of 1.00 and an EV to Sales ratio of 2.17, which suggest that the market may not fully recognize its potential. Additionally, the EV to EBITDA ratio stands at 38.38, reflecting a significant disparity compared to peers. In comparison to its industry peers, Azenta, Inc. has a notably high EV to EBITDA ratio, with Encompass Health Corp. at 12.89 and The Ensign Group, Inc. at 21.10, both of which are more attractive valuations. Furthermore, while Azenta is currently loss-making with a P/E ratio not applicable, it is essential to note that its return metrics, such as ROCE at -2.84% and ROE at -1.39%, indicate operational challenges. Despite these challenges, the stock's recent performance against the S&P 500 remains unreported, leaving an incomplete picture of its market standing.